Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 2

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 2
---
 par value $0.0001 per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement relating to its 2025 annual meeting of shareholders (the “2025 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2025 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

Daré Bioscience, Inc. and Subsidiaries Form 10-K – ANNUAL REPORT For the Fiscal Year Ended December 31, 2024 Table of Contents Page PART I 1 ITEM 1. Business 5 ITEM 1A. Risk Factors 58 ITEM 1B. Unresolved Staff Comments 112 ITEM 1C. Cybersecurity 112 ITEM 2. Properties 113 ITEM 3. Legal Proceedings 113 ITEM 4. Mine Safety Disclosures 113 PART II 114 ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 114 ITEM 6. Reserved 114 ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 114 ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk 131 ITEM 8. Financial Statements and Supplementary Data 131 ITEM 9. Changes in and Disagreement With Accountants on Accounting and Financial Disclosure 131 ITEM 9A. Controls and Procedures 131 ITEM 9B. Other Information 132 ITEM 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 132 PART III 133 ITEM 10. Directors, Executive Officers and Corporate Governance 133 ITEM 11. Executive Compensation 133 ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 133 ITEM 13. Certain Relationships and Related Transactions, and Director Independence 133 ITEM 14. Principal Accountant Fees and Services 133 PART IV 134 ITEM 15. Exhibits and Financial Statement Schedules 134 ITEM 16. Form 10-K Summary 140 Signatures 141 Financial Statements F-1

PART I CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, in particular ITEM 1. "BUSINESS," ITEM 7. "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS,”